Unither is a contract manufacturing organization (CMO) focused on a few premeasured dosage forms that are preferred by patients. Created in 1993 from the buyout of a Sanofi Group pharmaceutical manufacturing plant in France, which was generating €2.5 million in annual turnover at the time, Unither grew rapidly in the sterile unit-dose sector. Over the past 20 years, Unither has grown in its manufacturing activity while successfully developing new solutions, such as the Unistick. In the US, these are currently sterile blow-fill-seal (BFS), and Unistick liquid stick-packs. Unither Pharmaceuticals operates at an international level, having created a subsidiary in Brazil and another in 2013 in the USA through the buyout of UCB in the state of New York. This factory, with 250 people, has enabled them to become a leading global player in their field.
Contact
Laboratoire Unither Amiens
Espace Industriel Nord
151 Rue André Durouchez
CS 28028
80084 Amiens Cedex 2
France
Tel : + 33 (0)3 22 54 73 00
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its…
Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
See our Cookie Privacy Policy Here
